1207 related articles for article (PubMed ID: 31743235)
1. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
Chen JJ; Bhatti MT
Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
Tajfirouz DA; Bhatti MT; Chen JJ
Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
[TBL] [Abstract][Full Text] [Related]
4. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
5. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.
Chen JJ; Flanagan EP; Jitprapaikulsan J; López-Chiriboga ASS; Fryer JP; Leavitt JA; Weinshenker BG; McKeon A; Tillema JM; Lennon VA; Tobin WO; Keegan BM; Lucchinetti CF; Kantarci OH; McClelland CM; Lee MS; Bennett JL; Pelak VS; Chen Y; VanStavern G; Adesina OO; Eggenberger ER; Acierno MD; Wingerchuk DM; Brazis PW; Sagen J; Pittock SJ
Am J Ophthalmol; 2018 Nov; 195():8-15. PubMed ID: 30055153
[TBL] [Abstract][Full Text] [Related]
6. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
7. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
[TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
9. Optic neuritis in the era of biomarkers.
Chen JJ; Pittock SJ; Flanagan EP; Lennon VA; Bhatti MT
Surv Ophthalmol; 2020; 65(1):12-17. PubMed ID: 31425702
[TBL] [Abstract][Full Text] [Related]
10. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
[TBL] [Abstract][Full Text] [Related]
11. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
Ramanathan S; Prelog K; Barnes EH; Tantsis EM; Reddel SW; Henderson AP; Vucic S; Gorman MP; Benson LA; Alper G; Riney CJ; Barnett M; Parratt JD; Hardy TA; Leventer RJ; Merheb V; Nosadini M; Fung VS; Brilot F; Dale RC
Mult Scler; 2016 Apr; 22(4):470-82. PubMed ID: 26163068
[TBL] [Abstract][Full Text] [Related]
12. Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies.
Hassan MB; Stern C; Flanagan EP; Pittock SJ; Kunchok A; Foster RC; Jitprapaikulsan J; Hodge DO; Bhatti MT; Chen JJ
Am J Ophthalmol; 2020 Dec; 220():110-114. PubMed ID: 32707199
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
[TBL] [Abstract][Full Text] [Related]
16. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
17. Clinical and radiologic approach to 'typical' versus antibody-related optic neuritis.
Caron-Cantin M; Cestari DM; Fortin E
Curr Opin Ophthalmol; 2019 Nov; 30(6):412-417. PubMed ID: 31503075
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
[TBL] [Abstract][Full Text] [Related]
20. Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?
Papais Alvarenga RM; Araújo ACRAE; Nascimento ACB; Araujo NEC; Meneguette NS; Neri VC; Papais Alvarenga M; Filho HA; Barros PO; Bento CA; Schmidt SL; Vasconcelos CCF; Alvarenga MP
Mult Scler Relat Disord; 2020 Jul; 42():102082. PubMed ID: 32361664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
